Abbott Receives FDA Approval for Next-Gen Deep Brain Stimulation System with Directional Leads
Summary
Abbott announced FDA approval of its next-generation deep brain stimulation system featuring directional leads that allow physicians to steer stimulation more precisely to target areas. The system is approved for Parkinson's disease and essential tremor. The directional lead technology enables more personalized therapy by allowing stimulation to be shaped to each patient's unique anatomy and symptom profile.
Why it matters
Directional DBS technology represents an important advancement in deep brain stimulation, potentially allowing for more effective symptom control with fewer side effects. By steering stimulation away from areas that cause unwanted effects, directional leads could improve the therapeutic window for DBS therapy. Abbott's continued innovation in neuromodulation reflects the competitive dynamics driving technology advancement in the DBS market for movement disorders.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial